We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
RegeneRx Biopharmaceuticals’ dry eye candidate RGN-259 missed its primary endpoints in a Phase 2/3 trial, failing to show statistically significant improvements in either total ocular discomfort or total corneal fluorescein staining.